Rosuvastatin
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Infarction, Anterior Cerebral Artery
Conditions
Infarction, Anterior Cerebral Artery
Trial Timeline
Sep 1, 2015 → Sep 1, 2018
NCT ID
NCT02484027About Rosuvastatin
Rosuvastatin is a approved stage product being developed by AstraZeneca for Infarction, Anterior Cerebral Artery. The current trial status is unknown. This product is registered under clinical trial identifier NCT02484027. Target conditions include Infarction, Anterior Cerebral Artery.
What happened to similar drugs?
20 of 20 similar drugs in Infarction, Anterior Cerebral Artery were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00160745 | Phase 2 | Completed |
| NCT04846231 | Phase 2 | Completed |
| NCT02561845 | Pre-clinical | Withdrawn |
| NCT02484027 | Approved | UNKNOWN |
| NCT02077257 | Approved | UNKNOWN |
| NCT01837823 | Phase 2 | Completed |
| NCT01490398 | Approved | Completed |
| NCT01364220 | Phase 3 | Terminated |
| NCT00815659 | Approved | Completed |
| NCT00747149 | Approved | Completed |
| NCT00473655 | Approved | Completed |
| NCT00335699 | Approved | Completed |
| NCT00184951 | Phase 2 | Completed |
| NCT00240305 | Phase 3 | Completed |
| NCT00176332 | Phase 2 | Completed |
| NCT00228514 | Phase 3 | Completed |
| NCT00240266 | Phase 3 | Completed |
| NCT00241488 | Phase 3 | Completed |
| NCT00660764 | Pre-clinical | Completed |
| NCT00239681 | Phase 3 | Terminated |
Competing Products
20 competing products in Infarction, Anterior Cerebral Artery